{
    "nctId": "NCT03381092",
    "briefTitle": "Sentinel Lymph Node Biopsy in Clinically Node-negative Early Breast Cancer Patients After Neoadjuvant Chemotherapy",
    "officialTitle": "Sentinel Lymph Node Biopsy in Clinically Node-negative Early Breast Cancer Patients After Neoadjuvant Chemotherapy",
    "overallStatus": "UNKNOWN",
    "conditions": "Invasive Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 348,
    "primaryOutcomeMeasure": "Positive Rate of Axillary Sentinel Lymph Nodes.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Invasive breast cancer diagnosed with core needle needle biopsy;\n* Staging cT1b-2N0M0;\n* ER/PR positive cells ratio \\<10%, or HER2 positive (according to ASCO-CAP guidelines),and with chemotherapy indications;\n* Without chemotherapy contraindications, and planned or has started neoadjuvant chemotherapy (HER2 positive breast cancer neoadjuvant anti-HER2 treatment, or have adjuvant anti-HER2 treatment plan);\n* With axillary sentinel lymph node biopsy indications confirmed prior to neoadjuvant therapy;\n* Voluntarily join the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* History of malignant tumors.\n* With chemotherapy contraindications.\n* Recieved any form of surgery of primary tumor or axillary lymph nodes.\n* Refuse neoadjuvant chemotherapy.\n* Refuse assessment examinations.\n* Refuse to join the study.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}